Your browser doesn't support javascript.
loading
Autoantibodies neutralizing type I IFNs are present in ~4% of uninfected individuals over 70 years old and account for ~20% of COVID-19 deaths.
Bastard, Paul; Gervais, Adrian; Le Voyer, Tom; Rosain, Jérémie; Philippot, Quentin; Manry, Jérémy; Michailidis, Eleftherios; Hoffmann, Hans-Heinrich; Eto, Shohei; Garcia-Prat, Marina; Bizien, Lucy; Parra-Martínez, Alba; Yang, Rui; Haljasmägi, Liis; Migaud, Mélanie; Särekannu, Karita; Maslovskaja, Julia; de Prost, Nicolas; Tandjaoui-Lambiotte, Yacine; Luyt, Charles-Edouard; Amador-Borrero, Blanca; Gaudet, Alexandre; Poissy, Julien; Morel, Pascal; Richard, Pascale; Cognasse, Fabrice; Troya, Jesus; Trouillet-Assant, Sophie; Belot, Alexandre; Saker, Kahina; Garçon, Pierre; Rivière, Jacques G; Lagier, Jean-Christophe; Gentile, Stéphanie; Rosen, Lindsey B; Shaw, Elana; Morio, Tomohiro; Tanaka, Junko; Dalmau, David; Tharaux, Pierre-Louis; Sene, Damien; Stepanian, Alain; Megarbane, Bruno; Triantafyllia, Vasiliki; Fekkar, Arnaud; Heath, James R; Franco, José Luis; Anaya, Juan-Manuel; Solé-Violán, Jordi; Imberti, Luisa.
Afiliación
  • Bastard P; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France. jean-laurent.casanova@rockefeller.edu paul.bastard@institutimagine.org.
  • Gervais A; University of Paris, Imagine Institute, Paris, France.
  • Le Voyer T; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
  • Rosain J; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Philippot Q; University of Paris, Imagine Institute, Paris, France.
  • Manry J; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Michailidis E; University of Paris, Imagine Institute, Paris, France.
  • Hoffmann HH; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Eto S; University of Paris, Imagine Institute, Paris, France.
  • Garcia-Prat M; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Bizien L; University of Paris, Imagine Institute, Paris, France.
  • Parra-Martínez A; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Yang R; University of Paris, Imagine Institute, Paris, France.
  • Haljasmägi L; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
  • Migaud M; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
  • Särekannu K; Department of Pediatrics, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  • Maslovskaja J; Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain.
  • de Prost N; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Tandjaoui-Lambiotte Y; University of Paris, Imagine Institute, Paris, France.
  • Luyt CE; Pediatric Infectious Diseases and Immunodeficiencies Unit, Hospital Universitari Vall d'Hebron, Vall d'Hebron Research Institute, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona (UAB), Barcelona, Catalonia, Spain.
  • Amador-Borrero B; St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
  • Gaudet A; Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
  • Poissy J; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
  • Morel P; University of Paris, Imagine Institute, Paris, France.
  • Richard P; Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
  • Cognasse F; Institute of Biomedicine and Translational Medicine, University of Tartu, Tartu, Estonia.
  • Troya J; Service de Médecine Intensive Réanimation, Hôpitaux Universitaires Henri Mondor, Assistance Publique - Hôpitaux de Paris (AP-HP).
  • Trouillet-Assant S; Groupe de Recherche Clinique CARMAS, Faculté de Santé de Créteil, Université Paris Est Créteil, 51, Avenue du Maréchal de Lattre de Tassigny, 94010 Créteil Cedex, France.
  • Belot A; Avicenne Hospital, Assistance Publique Hôpitaux de Paris, Bobigny, INSERM U1272 Hypoxia & Lung, Bobigny, France.
  • Saker K; Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Médecine Intensive Réanimation, AP-HP, Paris, France.
  • Garçon P; INSERM UMRS_1166-iCAN, Institute of Cardiometabolism and Nutrition, Paris, France.
  • Rivière JG; Internal Medicine Department, Lariboisière Hospital, AP-HP, Paris University, Paris, France.
  • Lagier JC; University of Lille, U1019-UMR9017-Center for Infection and Immunity of Lille, Lille, France.
  • Gentile S; CNRS, UMR9017, Lille, France.
  • Rosen LB; INSERM, U1019, Lille, France.
  • Shaw E; Institut Pasteur de Lille, Lille, France.
  • Morio T; CHU Lille, Pôle de Réanimation, Hôpital Roger Salengro, Lille, France.
  • Tanaka J; University of Lille, U1019-UMR9017-Center for Infection and Immunity of Lille, Lille, France.
  • Dalmau D; CNRS, UMR9017, Lille, France.
  • Tharaux PL; INSERM, U1019, Lille, France.
  • Sene D; Institut Pasteur de Lille, Lille, France.
  • Stepanian A; CHU Lille, Pôle de Réanimation, Hôpital Roger Salengro, Lille, France.
  • Megarbane B; Etablissement Français du Sang, La Plaine-St Denis, France.
  • Triantafyllia V; UMR 1098 RIGHT, Inserm, EFS, Université de Franche-Comté, Besançon, France.
  • Fekkar A; Etablissement Français du Sang, La Plaine-St Denis, France.
  • Heath JR; SAINBIOSE, INSERM U1059, University of Lyon, Université Jean-Monnet-Saint-Etienne.
  • Franco JL; Etablissement Français du Sang, Auvergne Rhône-Alpes, St-Etienne, St-Etienne, France.
  • Anaya JM; Department of Internal Medicine, Infanta Leonor University Hospital, Madrid, Spain.
  • Solé-Violán J; Hospices Civils de Lyon, Lyon, France; International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France.
  • Imberti L; Joint Research Unit, Hospices Civils de Lyon-bio Mérieux, Hospices Civils de Lyon, Lyon Sud Hospital, Pierre-Bénite, France; International Center of Research in Infectiology, Lyon University, INSERM U1111, CNRS UMR 5308, ENS, UCBL, Lyon, France.
Sci Immunol ; 6(62)2021 08 19.
Article en En | MEDLINE | ID: mdl-34413139
Circulating autoantibodies (auto-Abs) neutralizing high concentrations (10 ng/mL, in plasma diluted 1 to 10) of IFN-α and/or -ω are found in about 10% of patients with critical COVID-19 pneumonia, but not in subjects with asymptomatic infections. We detect auto-Abs neutralizing 100-fold lower, more physiological, concentrations of IFN-α and/or -ω (100 pg/mL, in 1/10 dilutions of plasma) in 13.6% of 3,595 patients with critical COVID-19, including 21% of 374 patients > 80 years, and 6.5% of 522 patients with severe COVID-19. These antibodies are also detected in 18% of the 1,124 deceased patients (aged 20 days-99 years; mean: 70 years). Moreover, another 1.3% of patients with critical COVID-19 and 0.9% of the deceased patients have auto-Abs neutralizing high concentrations of IFN-ß. We also show, in a sample of 34,159 uninfected subjects from the general population, that auto-Abs neutralizing high concentrations of IFN-α and/or -ω are present in 0.18% of individuals between 18 and 69 years, 1.1% between 70 and 79 years, and 3.4% >80 years. Moreover, the proportion of subjects carrying auto-Abs neutralizing lower concentrations is greater in a subsample of 10,778 uninfected individuals: 1% of individuals <70 years, 2.3% between 70 and 80 years, and 6.3% >80 years. By contrast, auto-Abs neutralizing IFN-ß do not become more frequent with age. Auto-Abs neutralizing type I IFNs predate SARS-CoV-2 infection and sharply increase in prevalence after the age of 70 years. They account for about 20% of both critical COVID-19 cases in the over-80s, and total fatal COVID-19 cases.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Autoanticuerpos / Interferón Tipo I / COVID-19 Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Humans / Infant / Middle aged / Newborn Idioma: En Revista: Sci Immunol Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Autoanticuerpos / Interferón Tipo I / COVID-19 Tipo de estudio: Observational_studies / Risk_factors_studies Límite: Adolescent / Adult / Aged / Aged80 / Child / Child, preschool / Humans / Infant / Middle aged / Newborn Idioma: En Revista: Sci Immunol Año: 2021 Tipo del documento: Article Pais de publicación: Estados Unidos